NCT02426411View on ClinicalTrials.gov

Dose Ranging Trial to Determine the Safety and Efficacy of EMA401 in Patients With PHN

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 30, 2015

Primary Completion Date

October 31, 2016

Study Completion Date

December 31, 2016

Conditions
Neuralgia, Postherpetic
Interventions
DRUG

EMA401 200 mg

DRUG

EMA401 600 mg

DRUG

Placebo

Sponsors

Collaborators (1)

Syneos Health
All Listed Sponsors
collaborator

Syneos Health

OTHER

lead

Spinifex Pharmaceuticals Pty Ltd

INDUSTRY